Posts Tagged ‘FDA advisory committee’

NEW YORK TIMES: Denosumab, a new drug to prevent fractures in men undergoing prostate cancer hormone treatment, is likely to get FDA approval for high risk cases only. READ MORE>

An FDA advisory committee has voted against three of four possible uses for breast and prostate cancer patients whose therapy can weaken bones. The FDA will decide in October.

Read Full Post »